# A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention

> **NCT02630459** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 475 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Placebo
- **DRUG:** Erenumab
- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT02630459
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-06
- **Primary completion:** 2017-09-25
- **Final completion:** 2019-06-05
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630459, "A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02630459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*